☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
liver cancer
Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma
November 3, 2020
Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carc...
October 30, 2020
AstraZeneca's Imfinzi (durvalumab) + Tremelimumab Receive the US FDA's Orphan Drug Designation for Liver Cancer
January 20, 2020
Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications
October 31, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.